Thrombosis Research Institute provides the excellence in research, education and patient care. Thrombosis Research Institutes is one of the internationally renowned for innovative, multi-disciplinary research, they are dedicated to the study of thrombosis and related disorders. The Two research establishments in London and Bangalore are united by their shared mission: To provide excellence and development new strategies in thrombosis research, education and patient care and to prevent and treat thrombosis, saving millions of lives and thereby reducing healthcare costs. The Thrombosis Research Institute, London, UK (registered charity number 800365) was established in 1989, this was followed in 2006, with the founding of the Thrombosis Research Institute in Bangalore, India (registered charity number BNG (U) ANKL S.R/D. No. 117/03-04), Officially opened by the President of India, Dr A P J Abdul Kalam. The two Boards of Trustees in London and Bangalore institutions contribute to a joint and o do independent research programme. About Thrombosis: Thrombosis is nothing but clotting of blood inside a blood vessel which results in blocking the whole vein or artery and it is one of the main reasons for the cardiovascular diseases and mortality rate in the world. A blood can be clotted in any part of the body if it is clotted in an artery of the heart i.e., coronary artery, this overall results in heart attack and if there is blood clot in the brain is known as a stroke. When part of a clot has lodged in a lung artery results A pulmonary embolism. Our Strategy: Both Thrombosis Research Institutes committed to save millions of lives by reducing healthcare costs by inventing new advances in the detection, prevention and treatment of thrombosis and preventing long term disability The research activities of the two institutions, involves the drug discovery, basic clinical and epidemiological studies which are primarily concerned in understanding the disease process which helps in developing novel and inexpensive therapies for treating mainly who are at most in early age. Thrombosis Research Institute in London is committed to educate health professionals, increasing awareness among the public and patients. Achievements Major Contribution to Thrombosis Research: The multidisciplinary programmes in clinical research and laboratory resulted in major advances in venous thromboembolism. In 1965 the early detection, prevention and treatment of post-operative venous thromboembolism was started with a only two staff. In 1969 Vijay Kakkar described the history of deep vein thrombosis in surgical patients. By describing venous thromboembolism’s cause and effect. In the early 1970s, he established that a fixed low dose of heparin, an anticoagulant can prevent deep vein thrombosis/ pulmonary embolism could in surgical patients. In 1975, a major mortality outcome study coordinated by the Thrombosis Research Institute by Kakkar’s his original research resulted in preventing the peri and post-operative death from pulmonary embolism. This trial resulted saving seven lives for every 1,000 operated patients from embolism. In 1982, the first clinical evaluation of heparin in the prevention of deep vein thrombosis was done by staff at the Institute. Over the past 20 years the use heparin for antithrombotic therapy are used throughout the world and resulted in eradication of deaths due to thrombosis in high risk patients undergoing major surgery and resulted in saving approximately 300,000 lives per year worldwide. Current Projects: All our research projects are concerned with the mechanisms involved in blood coagulation, inflammation and atherogenesis in order to save many thousands of patient lives and the multi-disciplinary approach helps us to investigate the research at molecular level and with major bases in Bangalore, India as well as London, United Kingdom, we are currently accelerating our research projects. Collaborations: Thrombosis Research Institute work has saved millions of lives globally by improving worldwide protocol and therapies on thrombosis prevention and treatment. Being a member of Academic Health Science Partnership, and ucl Partners presently the TRI has its own medical development facility but even they also access through partnerships and also have collaboration to international research.